Medicine Grand Rounds: Cancer 2018: Have we Overpromised?

When:
November 14, 2018 @ 8:00 am – 9:00 am
2018-11-14T08:00:00-08:00
2018-11-14T09:00:00-08:00
Where:
LKSC Berg Hall
Li Ka Shing Building
291 Campus Drive, Palo Alto, CA 94305
USA
Cost:
Free
Contact:
Talia Ochoa
Medicine Grand Rounds: Cancer 2018: Have we Overpromised? @ LKSC Berg Hall | Palo Alto | California | United States

Presenter: Beverly Mitchell, MD

Director Emeritus and Senior Adviser, Stanford Cancer Institute

George E. Becker Professor in Medicine, and Professor, by courtesy, of Chemical and Systems Biology, Stanford University

Beverly S. Mitchell, MD, is the Director Emeritus and senior adviser for the Stanford Cancer Institute and is the George E. Becker Professor of Medicine at Stanford University. Before joining the Stanford faculty, Dr. Mitchell lead the Molecular Therapeutics Program at UNC Chapel Hill’s Lineberger Comprehensive Cancer Center, where she also served as Associate Director for Translational Research and Chief of the Division of Hematology/Oncology.  She served as Director of the Stanford Cancer Institute for 10 years.

She has authored over 130 peer-reviewed articles. She served as President of the American Society of Hematology (ASH) and was Chair of the Medical and Scientific Affairs Committee and Vice Chair for Medical and Scientific Affairs of the Leukemia and Lymphoma Society of America.
Dr. Mitchell’s current research relates to the development of new therapies for hematologic malignancies. She is interested in preclinical proof of principle studies on mechanisms inducing cell death and on metabolic targets involving nucleic acid biosynthesis in malignant cells. Recent studies have focused on the role of nucleolar proteins in cellular stress responses, including that induced by reactive oxygen species. She is also interested in the regulation of ribosomal RNA synthesis in hematopoietic stem and progenitor cells and in the role of dysregulated synthesis in bone marrow failure syndromes. in addition, her laboratory is involved in the translation of these studies into scientifically designed clinical trials.